Healthcare provider profile · identity verified

Lynne Dee Malain, MD

Internal Medicine · ROCHESTER, MN · NPI 1982836383

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	226	94
Amlodipine Besylate	Amlodipine Besylate	199	57
Lisinopril	Lisinopril	177	57
Levothyroxine Sodium	Levothyroxine Sodium	150	43
Losartan Potassium	Losartan Potassium	138	44
Gabapentin	Gabapentin	137	38
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	116	29
Omeprazole	Omeprazole	92	31
Alendronate Sodium	Alendronate Sodium	82	34
Metformin Hcl	Metformin Hcl	81	31
Simvastatin	Simvastatin	81	30
Metoprolol Succinate	Metoprolol Succinate	76	29
Metformin Hcl Er	Metformin Hcl	66	23
Albuterol Sulfate Hfa	Albuterol Sulfate	64	29
Hydrochlorothiazide	Hydrochlorothiazide	63	27
Rosuvastatin Calcium	Rosuvastatin Calcium	48	15
Trazodone Hcl	Trazodone Hcl	47	17
Furosemide	Furosemide	46	21
Pantoprazole Sodium	Pantoprazole Sodium	44	24
Tamsulosin Hcl	Tamsulosin Hcl	44	24
Acetaminophen-Codeine	Acetaminophen With Codeine	43	suppressed
Allopurinol	Allopurinol	41	suppressed
Fluticasone Propionate	Fluticasone Propionate	41	13
Atenolol	Atenolol	40	11
Carvedilol	Carvedilol	40	18
Xarelto	Rivaroxaban	40	suppressed
Citalopram Hbr	Citalopram Hydrobromide	36	suppressed
Famotidine	Famotidine	36	suppressed
Glipizide	Glipizide	32	suppressed
Lovastatin	Lovastatin	32	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	15
Montelukast Sodium	Montelukast Sodium	30	suppressed
Sertraline Hcl	Sertraline Hcl	30	suppressed
Finasteride	Finasteride	28	suppressed
Meclizine Hcl	Meclizine Hcl	28	12
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Tramadol Hcl	Tramadol Hcl	28	13
Acyclovir	Acyclovir	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	15
Lorazepam	Lorazepam	23	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Valsartan	Valsartan	23	suppressed
Eliquis	Apixaban	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Ozempic	Semaglutide	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Carisoprodol	Carisoprodol	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Estradiol	Estradiol	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Nystatin	Nystatin	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Baclofen	Baclofen	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Alprazolam	Alprazolam	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Naproxen	Naproxen	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error